Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis

Not Applicable

Completed

Conditions: Acne Vulgaris
Folliculitis

Interventions: Device: Ialuxid gel

Registration Number: NCT05345093

Lead Sponsor: BMG Pharma

Brief Summary: The Research Question of the present study is the following: in a population of men and women affected by acne vulgaris, and folliculitis, will Ialuxid® Gel (hydrogen peroxide, hyaluronic acid and glycine) improve the course of the disease, resulting in a decrease of the total number of lesions, results observed after 4 and 8 weeks after the beginning of the treatment?

Detailed Description: Ialuxid® Gel is a non-antibiotic treatment in gel indicated for use in a variety of skin conditions, and also in case of infection. Its principal ingredient is Ialuvance™ Complex, a proprietary association of hydrogen peroxide, hyaluronic acid, and glycine.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 66

Inclusion Criteria

Men or women aged ≥ 18 and ≤ 45 years.
Patients diagnosed with acne vulgaris, and folliculitis.

a. Only for patients with acne vulgaris: mild to moderate Global Acne Grading Scale score (≤ 30).
Patients willing to provide signed informed consent to clinical investigation participation.
Patients who agree to discontinue all dermatological treatment and procedures during the study.
Patients able to communicate adequately with the Investigator and to comply with the requirements for the study.

Exclusion Criteria

Pregnant woman, lactating woman, and man or woman of childbearing potential who is planning a pregnancy or is unwilling to use appropriate methods of contraception* during the study.

*Methods of contraception: hormonal contraceptive, intrauterine device or intrauterine system, double barrier method (condom with spermicide/diaphragm or cervical cap with spermicide), surgical sterilization (vasectomy, tubal ligation, etc.).
Patients with history of allergy or hypersensitivity to Hyaluronic Acid or to any other ingredients of Ialuxid® Gel or hypersensitivity skin reaction to Ialuxid® Gel based on skin test results.
History of anaphylaxis or severe complicated allergy symptoms.
Patients with any dermal systemic pathologies, such as systemic lupus erythematosus, psoriasis, scleroderma.
Patients who have used oral drugs for acne vulgaris, and folliculitis in the previous month.
Patients who have used topical therapies for acne vulgaris, and folliculitis in the previous month.
Use of concomitant treatments or procedures aimed to improve skin condition over the last six months before the enrolment, such as chemical peeling, dermabrasion, laser resurfacing.
Patients suffering from infectious diseases that would compromise participation, including herpes simplex virus infection, active hepatitis, or human immunodeficiency virus.
Patients at risk in term of precautions, warnings and contra-indications referred in the package insert of Ialuxid® Gel.
Patients with any facial aesthetic surgery (such as facial contouring surgery: rhinoplasty, chin, or cheek enhancement (through facial implant) or facial rejuvenation surgery: facelift, eyelid lift, neck lift or facial implants etc.) in the preceding 3 months before the enrolment.
Patients who received filler injections of any typology in the face in the preceding 3 months.
Patients who received botulinum toxin A injections in the face in the preceding 6 months.
Need to have direct or indirect contact with quaternary ammonium salts during the study.
Patients unlikely to cooperate.
Patients with any other medical condition that, in the opinion of the Investigator, would compromise participation or be likely to lead to hospitalization during the study.
Participation in an interventional clinical study or administration of any investigational agents in the previous 30 days.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ialuxid Gel	Ialuxid gel	twenty-two patients affected by acne vulgaris; twenty-two patients affected by folliculitis.

Primary Outcome Measures

Name	Time	Method
Serious Adverse Device event incidence	8 weeks	To evaluate the safety of the device trough Serious Adverse Device Event incidence assessed by Investigators at all visits and reported according to the current legislation.
Change in total number of lesions	8 weeks	To evaluate the overall performance of the medical device Ialuxid Gel in the treatment of acne vulgaris, and folliculitis in terms of change in the total number of lesions, according to lesions count performed by Investigator (sum of lesions present on the body area mainly interested by each disease, to be specified in CRF).
Serious Adverse event incidence	8 weeks	To evaluate the safety of the device trough Serious Adverse Event incidence assessed by Investigators at all visits and reported according to the current legislation.
Adverse Device event incidence	8 weeks	To evaluate the safety of the device trough Adverse Device Event incidence assessed by Investigators at all visits and reported according to the current legislation.
Anticipated Serious Adverse Device event incidence	8 weeks	To evaluate the safety of the device trough Anticipated Serious Adverse Device Event incidence assessed by Investigators at all visits and reported according to the current legislation.
Adverse event incidence	8 weeks	To evaluate the safety of the device trough Adverse Event incidence assessed by Investigators at all visits and reported according to the current legislation.
Unexpected Serious Adverse Device event incidence	8 weeks	To evaluate the safety of the device trough Unexpected Serious Adverse Device Event incidence assessed by Investigators at all visits and reported according to the current legislation.

Secondary Outcome Measures

Name	Time	Method
Treatment satisfaction questionnaire	8 weeks	To assess the patient satisfaction by means of the treatment satisfaction questionnaire, assessed by patient, providing their degree of satisfaction with the treatment on a four-point scale (very satisfied, satisfied, moderately satisfied, or not satisfied)
Investigator Global Assessment of Performance (IGAP)	8 weeks	To evaluate the global performance of Ialuxid® Gel by means of the Investigator Global Assessment of Performance (IGAP), assessed by Investigator, through photos taken at each visit. The scale evaluates the change on a 4 point scale from 1 meaning very good performance to 4 meaning poor performance)
Global Acne Grading System (GAGS)	8 weeks	To assess acne vulgaris severity by means of the Global Acne Grading System (GAGS) score, assessed by Investigator. Only for patients affected by acne vulgaris. The grading system score evaluates the acne severity from a minimum score of 0 (no acne) to \>39 (very severe acne).
Investigator Global Assessment of Performance (IGAS)	8 weeks	To evaluate the global safety of Ialuxid® Gel by means of the Investigator Assessment of Performance (IGAS) assessed by the Investigator, providing the safety on a four point scale from 4 meaning poor safety to 1 meaning very good safety.
Dermatology Life Quality Index (DLQI)	8 weeks	To assess the quality of life by means of the Dermatology Life Quality Index (DLQI) score, assessed by patients, providing the impact the disease had on the subjects life in various scenarios from not at all to very much
Change in total number of lesions	4 weeks	To evaluate the overall performance of the medical device Ialuxid® Gel in the treatment of acne vulgaris, and folliculitis in terms of change in the total number of lesions, according to lesions count performed by Investigator
Total Severity Score (TSS)	8 weeks	To assess the total number of patients having a decrease in the global severity of the disease by means of the Total Severity Score (TSS), assessed by Investigator. The scale evaluates of symptoms of each diseases (for folliculitis - pustule and inflammatory nodules; for acne vulgaris - comedones, papules, pustules, nodules, cysts, abscesses) from 0 (absent) to 3 (severe).
Patient Global Assessment of Performance (PGAS)	8 weeks	To evaluate the global safety of Ialuxid® Gel by means of the Patient Assessment of Performance (PGAS) assessed by the patient, providing the safety on a four point scale from 4 meaning poor safety to 1 meaning very good safety.

Trial Locations

Locations (1): SC Salvosan Ciobanca SRL
🇷🇴
Zalău, Salaj, Romania